Interferon can take 6-8 months to achieve a complete hematologic response. To manage patients during this period and avoid frequent phlebotomies, clinicians can prescribe a short, overlapping course of faster-acting hydroxyurea, providing immediate control while transitioning to the long-term therapy.

While not yet validated, ctDNA is being used by clinical experts as a de-escalation tool to provide confidence when stopping long-term maintenance therapies like PARP inhibitors. This novel application focuses on reducing treatment burden rather than solely detecting disease progression.

Interferon therapy is being evaluated in a distinct niche from JAK inhibitors. It is targeted at patients with early or low-risk myelofibrosis, not for immediate symptom control, but with the strategic goal of potentially modifying the disease course and slowing its natural progression.

In current CLL practice, a positive MRD result after fixed-duration therapy does not trigger a change in treatment, such as extending therapy. It serves as a prognostic tool to inform the patient and physician about the likely duration of remission and the need for closer monitoring.

Immunotherapy is now inducing complete responses in a small subset of advanced HCC patients. This success presents a novel challenge, as there is no data to guide decisions on treatment duration, forcing difficult discussions about stopping therapy in patients who may be cured.

Despite label recommendations for rapid dose escalation of ropeginterferon, experienced clinicians advocate for a slower, more patient-centric approach. This prioritizes long-term tolerability and adherence, which is crucial for achieving disease modification, over achieving rapid hematologic control.

While continuous therapy remains the official standard of care for mHSPC, there's a growing consensus for individualized de-intensification. For patients with a sustained, undetectable PSA (e.g., for two years), clinicians are increasingly comfortable discussing stopping all treatments to improve quality of life and reduce toxicity.

Despite the appeal of stopping treatment, a key insight from clinical practice is that patients' most critical question remains which therapy offers the longest period of remission, often overriding factors like treatment duration and oral-only options.

Proactively, some hematologists now offer interferon-based therapy to very young, asymptomatic low-risk PV patients. The rationale is to leverage the drug's potential for disease modification by reducing JAK2 allele burden early on, even though this is not yet a formal guideline-supported indication.